DRD2 and metabolic dysfunction-associated steatohepatitis: Notably, the selective inhibition of YAP in macrophages through Dopamine receptor D2 (DRD2) antagonism has demonstrated promise in preventing liver fibrosis, making it a potential candidate for treating nonalcoholic steatohepatitis (NASH) (69).